Essex Bio-Technology Limited has announced that its indirect subsidiary, Guangdong Hanfeng Baisheng Pharmaceutical Company Limited, has received approval from the National Medical Products Administration (NMPA) for the registration and commercialisation of multi-dose Sodium Hyaluronate Eye Drops (0.3%) in mainland China. The approved product is indicated for the treatment and symptomatic relief of various intrinsic and extrinsic ocular diseases, including Sjögren's syndrome, Stevens-Johnson syndrome, dry eye syndrome, and injuries caused by surgery, drugs, trauma, or contact lens use. No other beneficiary organizations were mentioned in the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Essex Bio-Technology Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260109-11986578), on January 09, 2026, and is solely responsible for the information contained therein.